Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Olsalazine
Drug ID BADD_D01607
Description Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.
Indications and Usage For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.
Marketing Status approved
ATC Code A07EC03
DrugBank ID DB01250
KEGG ID D08295
MeSH ID C032587
PubChem ID 22419
TTD Drug ID D00KRE
NDC Product Code Not Available
UNII ULS5I8J03O
Synonyms olsalazine | azodisalicylate | Dipentum | Rasal | olsalazine sodium | disodium 5,5'-azodisalicylate | sodium diazosalicylate | olsalazine, disodium salt | azodisal sodium | disodium azodisalicylate | CJ-91B
Chemical Information
Molecular Formula C14H10N2O6
CAS Registry Number 15722-48-2
SMILES C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thyroid disorder05.02.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Tubulointerstitial nephritis20.05.02.002--Not Available
Lymphatic disorder01.09.01.003--Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder15.06.01.006; 10.04.04.026--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages